Lecanemab Receives Priority Review Status in Japan
Go back to Lecanemab Receives Priority Review Status in Japan| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 227.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $227.60 | 52 Week High | $333.65 | |||
| Open | $227.60 | 52 Week Low | $223.02 | |||
| Day High | $227.60 | P/E | 29.14 | |||
| Day Low | $227.60 | EPS | $7.81 | |||
| Volume | 78 | |||||
